Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.
Hypocalcemia and an increase in creatinine level are the most important serious effects associated with foscarnet (PFA) therapy. In an animal model, we have explored the potential protective role of liposome-encapsulated foscarnet (LE-PFA) on these metabolic abnormalities. PFA administered as one bo...
Gespeichert in:
| Veröffentlicht in: | Antimicrob Agents Chemother |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society for Microbiology (ASM)
1995
|
| Schlagworte: | |
| Online-Zugang: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC162866/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8540701/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.39.9.1973 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|
